Assessing the appropriateness of combining economic data from multinational clinical trials

J.R. Cook; M.F. Drummond; H. GLick; J.F. Heyse

doi:10.1002/sim.1389

Assessing the appropriateness of combining economic data from multinational clinical trials

J.R. Cook, M.F. Drummond, H. GLick, J.F. Heyse

Centre for Health Economics

Research output: Contribution to journal › Article › peer-review

Abstract

Because of the potential for large variability among countries in the utilization and cost of health care resources, it is important to assess the appropriateness of combining economic data across the countries in a multinational clinical economic trial. We show how available tests for interaction can be applied to economic endpoints, including cost-effectiveness ratios and net health benefits. This analysis includes a characterization of possible interactions being quantitative or qualitative in nature. In the absence of interaction, a pooled estimate of the economic endpoint should be representative of the participating countries. We explore the analytic issues by further analysing data from the Scandinavian Simvastatin Survival Study (4S). Copyright (C) 2003 John Wiley Sons, Ltd.

Original language	English
Pages (from-to)	1955-1976
Number of pages	22
Journal	Statistics in Medicine
Volume	22
Issue number	12
DOIs	https://doi.org/10.1002/sim.1389
Publication status	Published - 30 Jun 2003

Keywords

multinational clinical trials
interaction
cost-effectiveness
net health benefits
SCANDINAVIAN SIMVASTATIN SURVIVAL
COST-EFFECTIVENESS ANALYSIS
NET HEALTH BENEFITS
QUALITATIVE INTERACTIONS
MODELS

Access to Document

10.1002/sim.1389

http://dx.doi.org/10.1002/sim.1389

Cite this

@article{a00649ec91784493abc3b70f64d3b203,

title = "Assessing the appropriateness of combining economic data from multinational clinical trials",

abstract = "Because of the potential for large variability among countries in the utilization and cost of health care resources, it is important to assess the appropriateness of combining economic data across the countries in a multinational clinical economic trial. We show how available tests for interaction can be applied to economic endpoints, including cost-effectiveness ratios and net health benefits. This analysis includes a characterization of possible interactions being quantitative or qualitative in nature. In the absence of interaction, a pooled estimate of the economic endpoint should be representative of the participating countries. We explore the analytic issues by further analysing data from the Scandinavian Simvastatin Survival Study (4S). Copyright (C) 2003 John Wiley Sons, Ltd.",

keywords = "multinational clinical trials, interaction, cost-effectiveness, net health benefits, SCANDINAVIAN SIMVASTATIN SURVIVAL, COST-EFFECTIVENESS ANALYSIS, NET HEALTH BENEFITS, QUALITATIVE INTERACTIONS, MODELS",

author = "J.R. Cook and M.F. Drummond and H. GLick and J.F. Heyse",

year = "2003",

month = jun,

day = "30",

doi = "10.1002/sim.1389",

language = "English",

volume = "22",

pages = "1955--1976",

journal = "Statistics in Medicine",

issn = "0277-6715",

publisher = "Wiley-Blackwell",

number = "12",

}

TY - JOUR

T1 - Assessing the appropriateness of combining economic data from multinational clinical trials

AU - Cook, J.R.

AU - Drummond, M.F.

AU - GLick, H.

AU - Heyse, J.F.

PY - 2003/6/30

Y1 - 2003/6/30

N2 - Because of the potential for large variability among countries in the utilization and cost of health care resources, it is important to assess the appropriateness of combining economic data across the countries in a multinational clinical economic trial. We show how available tests for interaction can be applied to economic endpoints, including cost-effectiveness ratios and net health benefits. This analysis includes a characterization of possible interactions being quantitative or qualitative in nature. In the absence of interaction, a pooled estimate of the economic endpoint should be representative of the participating countries. We explore the analytic issues by further analysing data from the Scandinavian Simvastatin Survival Study (4S). Copyright (C) 2003 John Wiley Sons, Ltd.

AB - Because of the potential for large variability among countries in the utilization and cost of health care resources, it is important to assess the appropriateness of combining economic data across the countries in a multinational clinical economic trial. We show how available tests for interaction can be applied to economic endpoints, including cost-effectiveness ratios and net health benefits. This analysis includes a characterization of possible interactions being quantitative or qualitative in nature. In the absence of interaction, a pooled estimate of the economic endpoint should be representative of the participating countries. We explore the analytic issues by further analysing data from the Scandinavian Simvastatin Survival Study (4S). Copyright (C) 2003 John Wiley Sons, Ltd.

KW - multinational clinical trials

KW - interaction

KW - cost-effectiveness

KW - net health benefits

KW - SCANDINAVIAN SIMVASTATIN SURVIVAL

KW - COST-EFFECTIVENESS ANALYSIS

KW - NET HEALTH BENEFITS

KW - QUALITATIVE INTERACTIONS

KW - MODELS

U2 - 10.1002/sim.1389

DO - 10.1002/sim.1389

M3 - Article

SN - 0277-6715

VL - 22

SP - 1955

EP - 1976

JO - Statistics in Medicine

JF - Statistics in Medicine

IS - 12

ER -